반응식
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C:9]([NH:11][NH:12][C:13]2[N:14]=[N:15][C:16]([C:26]3[CH:31]=[CH:30][CH:29]=[CH:28][C:27]=3[Cl:32])=[C:17]([C:19]3[CH:24]=[CH:23][C:22]([Cl:25])=[CH:21][CH:20]=3)[CH:18]=2)=O)=[CH:4][CH:3]=1.[Cl-].[Cl-].C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.ClC1C=CC=CC=1C1C(C2C=CC(Cl)=CC=2)=CC2N(C(CC3CCCCC3)=NN=2)N=1>>[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C:9]2[N:14]3[N:15]=[C:16]([C:26]4[CH:31]=[CH:30][CH:29]=[CH:28][C:27]=4[Cl:32])[C:17]([C:19]4[CH:24]=[CH:23][C:22]([Cl:25])=[CH:21][CH:20]=4)=[CH:18][C:13]3=[N:12][N:11]=2)=[CH:4][CH:3]=1참가 물질
4
반응물 3
생성물 1
실험 절차
The title compound (50 mg, 54%) as a white powder was prepared from 2-(4-chlorophenyl)-N′-(6-(2-chlorophenyl)-5-(4-chlorophenyl)pyridazin-3-yl)acetohydrazide (96 mg, 0.2 mmol) and triphenylphosphine dichloride (220 mg,0.66 mmol) according to the procedures described for 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-(cyclohexylmethyl)-[1,2,4]triazolo[4,3-b]pyridazine (Example 7B). HPLC/MS (method A): retention time=4.12 min, (M+H)+=465.2.
출처 및 근거
- ORD 기록
- ord-d397fa5ec9954711bf8041bf622dbb4d
- 출처 데이터셋
- uspto-grants-2009_12
- 특허 번호
- US07632837B2
연결된 노트
불러오는 중…